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Abstract The small phosphoprotein pCPI-17 inhibits myosin light-chain phosphatase (MLCP).
Current models postulate that during muscle relaxation, phosphatases other than MLCP
dephosphorylate and inactivate pCPI-17 to restore MLCP activity. We show here that such
hypotheses are insufficient to account for the observed rapidity of pCPI-17 inactivation in
mammalian smooth muscles. Instead, MLCP itself is the critical enzyme for pCPI-17
dephosphorylation. We call the mutual sequestration mechanism through which pCPI-17 and MLCP
interact inhibition by unfair competition: MLCP protects pCPI-17 from other phosphatases, while
pCPI-17 blocks other substrates from MLCP’s active site. MLCP dephosphorylates pCPI-17 at a
slow rate that is, nonetheless, both sufficient and necessary to explain the speed of pCPI-17
dephosphorylation and the consequent MLCP activation during muscle relaxation.
DOI: 10.7554/eLife.24665.001
Introduction
The phosphorylation of certain small proteins converts these polypeptides into inhibitors of PPP fam-
ily phosphatases [reviewed by (Eto and Brautigan, 2012)]. These phosphoproteins have extremely
strong affinities for the holoenzymes they target with IC50 values in the nanomolar/ subnanomolar
range. Given that the binding of phosphatase and phosphorylated inhibitor is so tight, how can the
enzyme’s activity be restored quickly when the phosphatase needs to be reactivated?
Current models assume that the phosphorylated inhibitors act as pseudosubstrates that bind to
the phosphatase’s active site, blocking access of genuine substrates (Desdouits et al., 1995;
Eto et al., 2004; Wakula et al., 2003). Either the enzyme cannot dephosphorylate the pseudosub-
strate, or the dephosphorylation is too slow to contribute meaningfully to the system’s reboot. Thus,
in these models, the inhibition can only be relieved by dissociation of the phosphorylated inhibitor
from the enzyme and its subsequent dephosphorylation by other phosphatases. We argue that this
scenario is incompatible with rapid changes of cellular state, because the very tight binding of the
inhibitor to the phosphatase protects the inhibitor from other enzymes. Instead, the inhibited
enzyme itself must dephosphorylate the inhibitor at a carefully calibrated rate that is slow enough to
maintain inhibition but fast enough to permit speedy physiological responses.
We examine here whether this idea, which we call inhibition by unfair competition, might contrib-
ute to the rapidity of smooth muscle relaxation that occurs after treatment with vasodilators. We
focus on the regulation of myosin light-chain phosphatase (MLCP), an enzyme comprised of a PP1
catalytic subunit and regulatory subunit MYPT1. MLCP targets the myosin regulatory light chain
(MRLC) and other proteins including ezrin/radixin/moesin (ERM) to affect cytoskeletal organization in
smooth muscle and nonmuscle cells [reviewed in (Grassie et al., 2011; Hartshorne et al., 1998;
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Ito et al., 2004)]. Because dephosphorylation of MRLC deactivates myosin motor activity, MLCP is
also a critical determinant of smooth muscle force: Agonist-mediated MLCP inhibition augments
force development (Hartshorne et al., 1998; Isotani et al., 2004; Ito et al., 2004; Somlyo and
Somlyo, 2003), while nitric oxide simulation causes rapid MLCP re-activation concurrent with
smooth muscle relaxation (Etter et al., 2001; Lubomirov et al., 2006; Somlyo and Somlyo, 2003).
Genetic experiments have validated the indispensability of MLCP: Ablation of MYPT1 in mice causes
embryonic lethality, while conditional knockout of MYPT1 in smooth muscles slows vasodilation and
elevates blood pressure [reviewed in (Grassie et al., 2012; Hartshorne et al., 1998; Ito et al.,
2004; Qiao et al., 2014)].
Smooth muscle, neurons, and other cells contain a small endogenous regulatory protein specific
to MLCP, named CPI-17 (Eto et al., 1995, 1997). This 17 kDa polypeptide becomes an MLCP inhibi-
tor when it is phosphorylated at Thr38 by any of several kinases, including PKC and ROCK, that are
activated when smooth muscle is exposed to agonists [reviewed in (Eto, 2009; Eto and Brautigan,
2012)]. pCPI-17 binds tightly to MLCP with pThr38 occupying the enzyme’s active site (Eto, 2009;
Eto et al., 2007; Hayashi et al., 2001), thereby inactivating MLCP and increasing both MRLC phos-
phorylation and tissue contractility (Li et al., 1998). CPI-17 Thr38 and MRLC phosphorylation levels
coordinately correspond with smooth muscle contraction during many physiological processes within
smooth muscles and other cell types [e.g. (Deng et al., 2002; Eto et al., 2002; Li et al., 1998;
Niiro et al., 2003; Watanabe et al., 2001)].
Our concern here is the dephosphorylation of CPI-17 and reactivation of MLCP, which occur in
parallel with rapid relaxation of smooth muscles within seconds of nitric oxide stimulation
(Etter et al., 2001; Kitazawa et al., 2003, 2009). Previous investigators have assumed that hydroly-
sis of pCPI-17 by MLCP is negligible and therefore envision that pCPI-17 must first dissociate from
MLCP to allow other enzymes (hereafter called ‘PPU’ for ‘Protein Phosphatase Unknown’) to then
rapidly dephosphorylate the freed inhibitor. Some investigators believe that these PPUs are PP1-
containing holoenzymes different from MLCP (Eto and Brautigan, 2012; Eto et al., 2004; Kita-
zawa, 2010), but others concluded that the CPI-17 dephosphorylating enzymes are PP2A
(Hersch et al., 2004; Obara et al., 2010; Takizawa et al., 2002) and/or PP2C (Takizawa et al.,
2002). However, regardless of the identity of PPU, these previous models do not adequately con-
sider the consequences of the very tight binding of pCPI-17 to MLCP, which some experiments sug-
gest is subnanomolar (Eto et al., 1995, 1997, 2000). This binding could protect pCPI-17 from any
PPU enzymes, implying that MLCP reactivation must depend on its own dephosphorylation of its
own inhibitor by the unfair competition principle.
Evaluating this possibility requires careful quantitative analysis. To this end, we have measured
the key parameters including the pCPI-17/MLCP and pCPI-17/PPU dephosphorylation kinetic con-
stants, the effective PPU concentration (which we resolve into two separate components), and the
effect of competing substrates on the dephosphorylation of pCPI-17 by PPU and MLCP. We use
these and prior experimental values to model quantitatively the time-courses of pCPI-17 dephos-
phorylation and MLCP reactivation during vasodilation. We show that, because MLCP effectively
protects pCPI-17 against other phosphatases, only models that include MLCP’s dominating dephos-
phorylation of pCPI-17 can explain the experimental physiological measurements (Kitazawa et al.,
2009).
We have previously shown that a similar unfair competition mechanism is important for the
release of PP2A-B55 from inhibition by phosphorylated Endosulfine (pEndos) during exit from mito-
sis (Williams et al., 2014). The fact that this mechanism operates to control two different phospha-
tases of the PPP family [PP2A-B55 and PP1-MYPT1 (MLCP)] suggests that it is ancient and evolved
prior to the duplication and divergence of PPP phosphatase genes in early eukaryotes.
Results
Current models for pCPI-17 inactivation are unlikely to account for the
rapidity of smooth muscle relaxation
Adding the vasodilator sodium nitroprusside to contracted rabbit femoral artery leads to maximal
dephosphorylation of pCPI-17 with a half-life t1/2 ~ 10 s, resulting in near-simultaneous phosphoryla-
tion of the myosin regulatory light chain and a decrease in contractile force soon thereafter
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(Kitazawa et al., 2009). As described in the Introduction, current models posit that pCPI-17 dephos-
phorylation is accomplished solely by PPU enzymes. Is this assumption consistent with the observed
speed of the process? We argue that the answer is likely ‘no’ under physiological conditions.
Figure 1A shows the fastest mechanism by which such models could operate: PPU enzymes
immediately dephosphorylate any pCPI-17 that dissociates from MLCP, and the dephosphorylated
CPI-17 is not rephosphorylated. The rate-limiting step of this scenario is simply the off-rate (koff) for
the dissociation of pCPI-17 from MLCP; that is, koff = log 2/t1/2 ~ 0.07 s
 1. However, this model is an
oversimplification that ignores two important counteracting processes: rebinding of released pCPI-
17 and regeneration of pCPI-17 from CPI-17.
These processes are likely to be important because prior experiments, combined with the lower
bound on koff required by the physiological rate, indicate that the pCPI-17/MLCP association con-
stant, kon, must be very high. Reported measurements for the IC50 of the inhibition of MLCP by thio-
phosphorylated CPI-17 [thio(p)CPI-17], which cannot be dephosphorylated, fall within the range of
0.12–6 nM (Erdo˝di et al., 2003; Eto et al., 1995, 1997, 2000, 2004; Hayashi et al., 2001).
Because, for tight-binding inhibitors, the Ki is lower than the IC50 (see Supplementary file 1), we can
estimate that kon (= koff/Ki) is minimally 1.2  10
7 M 1 s 1 and would need to be more than 6  108
M 1 s 1 if the Ki were as low as 0.12 nM. Such association rates are very fast: In a recent tabulation
of the kinetic parameters of 144 protein complexes, only two had kon values in excess of 1  10
8
M 1 s 1 (Archakov et al., 2003; Moal and Bates, 2012). In contrast, the corresponding association
constants for the potential PPU enzymes are probably less than 105 M 1 s 1 (McWhirter et al.,
2008; Pan et al., 2015; Price and Mumby, 2000). Therefore, unless the concentration of accessible
PPU is orders of magnitude greater than the concentration of unbound MLCP, rebinding will
strongly retard dephosphorylation by PPU.
Fast rebinding would also sequester pCPI-17 regenerated from CPI-17 by kinases such as PKC
and ROCK, which likely retain residual activity during smooth muscle relaxation. Such residual kinase
activity is particularly likely when vasodilators are added in the presence of agonists such as hista-
mine (Etter et al., 2001) or phenylephrine (Kitazawa et al., 2009; Shibata et al., 2015). As one
example, two indicators of ROCK activity (pRhoA Ser188 and pMYPT1 Thr853) remained almost
unchanged after vasodilator administration even when pCPI-17 decreased to a minimum level
(Kitazawa et al., 2009).
Figure 1B presents a more realistic model that accounts for these counteracting processes. We
show below that the Km for pCPI-17 lies at the lower end of the reported thio(p)CPI-17 IC50 range
and is ~0.5 nM. Thus, even in this model, koff cannot be much higher than 0.07 s
 1 because the req-
uisite kon [= (koff + kcat)/Km] would be unrealistically high. The net rates at which pCPI-17 is dephos-
phorylated and free MLCP is created therefore must be slower than for the model in Figure 1A to a
degree that depends on the relative concentrations and kinetic properties of all the players (CPI-17,
MLCP, PPU, and PKC/ROCK). We present below a mathematical treatment of the Figure 1B model
using values for these parameters determined from the literature and from our own experiments.
For the time being, we emphasize simply that the actual rate of MLCP reactivation observed experi-
mentally [t1/2 » 10 s; (Kitazawa et al., 2009)] is approximately 10-fold faster than the rate achiev-
able in cells through the Figure 1B model.
MLCP can dephosphorylate pCPI-17 at a physiologically relevant rate
The discussion above suggests that the rapid reactivation of MLCP requires some method to rid the
enzyme of the pCPI-17 inhibitor other than simple dissociation. The obvious strategy would be for
MLCP itself to dephosphorylate pCPI-17, as indicated in Figure 1C. This idea is plausible because
pThr38 of MLCP- bound pCPI-17 is located at the enzyme’s active site (Eto, 2009; Eto et al., 2007).
However, because it is small, it has been difficult to measure the rate of MLCP-mediated pCPI-17
dephosphorylation, and previous reports have only been able to place an upper bound (<0.1 s 1) on
its value (Hayashi et al., 2001). A kcat toward the upper limit of this range would be consistent with
the model in Figure 1C, but a significantly smaller value would not. Therefore, it was important to
determine if MLCP can dephosphorylate pCPI-17 at a rate fast enough to account for its dephos-
phorylation during muscle relaxation.
To this end, we prepared MLCP by transiently transfecting HEK-293 CRL-1573 cells with a con-
struct overexpressing FLAG-tagged MYPT1. Figure 2 shows that a complex containing PP1b/d
(PPP1CB) and MYPT1 was obtained. This preparation lacks a small M20 subunit that is found in
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Figure 1. Models for MLCP reactivation. (A) A simplistic model in which pCPI-17 is dephosphorylated only by
other phosphatases (PPU) immediately after it dissociates from MLCP. The rate-limiting step for MLCP reactivation
is the dissociation, whose rate is koff. (B) A more realistic scenario in which pCPI-17 freed by dissociation can
rebind to free MLCP, and in which pCPI-17 is in an equilibrium with unphosphorylated CPI-17 that depends on the
Figure 1 continued on next page
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MLCP purified from tissues but whose role has never been clarified (Ito et al., 2004), so we per-
formed multiple tests of the enzyme’s functional authenticity. Consistent with the known activities of
MLCP, we found that the complex we purified is able to dephosphorylate the myosin regulatory light
chain (pMRLC); the C terminal domain (pC-ERMAD) of ERM proteins, which are physiological MLCP
substrates (Eto et al., 2005, 2000; Fukata et al., 1998)]; and the nonspecific substrate myelin basic
protein (pMyBP). The assays with all three substrates (Figure 2—figure supplement 1A–C) were lin-
ear with respect to time and enzyme concentrations under the experimental conditions used [nota-
bly, in the absence of Mn2+, which can induce artifactual activities of PPP phosphatases
(Watanabe et al., 2003)]. Moreover, as shown below, dephosphorylation of all three substrates was
inhibited by the drugs okadaic acid and calyculin A, with IC50 values in the identical range of pub-
lished studies. The purified recombinant complex (Figure 2A) thus has properties very similar to
Figure 1 continued
relative activities of the kinases (PKC) and phosphatases (PPU) involved. The rate of MLCP inactivation must
necessarily be slower than that in (A). (C) Unfair competition. pCPI-17 is removed from MLCP by
dephosphorylation as well as by dissociation. Free pCPI-17 and unphosphorylated CPI-17 are in an equilibrium
determined by the relative activities of the kinases (PKC) and phosphatases (MLCP and PPU) involved. When the
concentration of pCPI-17 is less than or equal to the concentration of MLCP, the very low Km ensures that almost
all pCPI-17 dephosphorylation is accomplished by MLCP.
DOI: 10.7554/eLife.24665.002
Figure 2. Preparation of MLCP. HEK-293 CRL-1573 cells were transformed with empty vector, with a construct
overexpressing a FLAG-tagged version of the B56a regulatory subunit of PP2A for comparison, or with a construct
overexpressing FLAG-MYPT1. Phosphatase holoenzymes were then purified as previously described (Adams and
Wadzinski, 2007; Williams et al., 2014) and stabilized by the addition of bovine serum albumin (BSA). The
myosin phosphatase holoenzyme in the third lane has both FLAG-MYPT1 and PP1b/d in roughly equal
stoichiometry; the identity of these proteins was verified by Western blotting with anti-FLAG and with antibodies
specifically directed against the a, b/d, and g isoforms of the PP1 catalytic subunit (data not shown).
DOI: 10.7554/eLife.24665.003
The following figure supplement is available for figure 2:
Figure supplement 1. Phosphatase activities of the MLCP preparation shown in Figure 2.
DOI: 10.7554/eLife.24665.004
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those of authentic MLCP. Another study recently reached the same conclusion for PP1b/d-MYPT1
complex purified in substantially the same way; importantly, the presence or absence of the M20
subunit had no obvious effect on the activities of the complex (Khasnis et al., 2014).
Wild-type CPI-17 contains two sites that can be phosphorylated by PKC (Eto et al., 1995), Thr38
(the major phosphosite that converts CPI-17 into an MLCP inhibitor) and the minor site Ser12 [which
lies outside the inhibitory domain and regulates the protein’s nuclear import; (Eto et al., 2013)]. So
that we could quantitate accurately phosphorylation/dephosphorylation at the single Thr38 site, we
created recombinant CPI-17 with a Ser12-to-Ala12 mutation. The Ala12 mutant behaved identically to
the wild-type protein as an MLCP inhibitor (see Materials and methods). Figure 2—figure supple-
ment 1F shows that this recombinant MLCP also dephosphorylates pCPI-17, although quite slowly,
with a catalytic rate kcat ~0.08 s
 1. Combining this measurement with values obtained in the addi-
tional experiments described below (Figures 3, 4 and 5) gave a mean estimate of kcat = 0.06 ± 0.01
s 1 (n = 4) at 30˚C, which was used for subsequent analyses (Table 1). This value for the dephos-
phorylation of pCPI-17 by MLCP is more than 100-fold lower than the kcat of 10.7–13.7 s
 1 previously
measured by other investigators for the dephosphorylation of the myosin regulatory light chain
(MRLC) by the same enzyme (Feng et al., 1999a; Ichikawa et al., 1996), and it is also very slow
compared with the action of other phosphatases on pCPI-17 [(Eto et al., 2004; Hersch et al., 2004;
Takizawa et al., 2002) and see below]. However, it is fast enough to account for the physiological
dephosphorylation rate discussed in the Introduction. And indeed, if the kcat was substantially higher
than 0.1 s 1, pCPI-17 would be unable to inhibit MLCP.
The Km of the pCPI-17/MLCP interaction is extraordinarily low
Although MLCP dephosphorylates pCI-17 much more slowly than other phosphatases targeting the
same substrate [(Eto et al., 2004; Hersch et al., 2004; Takizawa et al., 2002) and see below], their
association might be sufficiently tight so as to shield pCPI-17 from any possible PPU phosphatases.
Figure 3. Dephosphorylation of pCPI-17 by MLCP as a function of pCPI-17 concentration. All assays contained 0.1 nM MLCP and were performed for 3
min at 30˚C in a total volume of 8 mL. The experiment was replicated in triplicate (n = 3); error bars represent standard deviations. Data were analyzed
by non-linear regression to Michaelis-Menten kinetics with Prism 6 software (GraphPad Software, Inc., La Jolla, CA). For this experiment,
Km = 3.03 ± 0.22 nM; kcat = 0.059 ± 0.002 s
 1.
DOI: 10.7554/eLife.24665.005
The following figure supplement is available for figure 3:
Figure supplement 1. Dephosphorylation of pCPI-17 by MLCP as a function of pCPI-17 concentration.
DOI: 10.7554/eLife.24665.006
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Figure 4. Determining the pCPI-17/MLCP Km by competitive inhibition. (A) Inhibition of MLCP by okadaic acid (OA). Enzyme assays in the presence of
increasing levels of OA were performed with the indicated substrates at the indicated concentrations; in all assays, the concentration of MLCP was 0.1
nM. Values are presented as a percentage of the average of four control reactions for each substrate without OA. For pCPI-17, each point represents
the average, and error bars the standard deviation, of five trials (n = 5); for phosphorylated myosin regulatory light chain (pMRLC), n = 4; for pC-
Figure 4 continued on next page
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Figure 4 continued
ERMAD, n = 2; for pMyelin Basic Protein (pMyBP), n = 1. Because the MLCP concentration is very low, the IC50s of the pMRLC, pMyBP, and pC-ERMAD
reactions must be close to the Ki for OA, which is therefore ~20 nM. The ~10–20 larger IC50 with pCPI-17 indicates that this substrate can compete
effectively with OA because its Km is smaller than the Ki. Indeed, the best-fit Km determined by nonlinear regression of this and a similar experiment
using 8.75 nM pCPI-17 (n = 3; not shown) is 0.59 ± 0.05 nM (see Supplementary file 1). (B) Inhibition of MLCP by calyculin A. Enzyme assays in the
presence of increasing levels of calyculin A were performed with pCPI-17 or with pC-ERMAD at the concentrations indicated; the concentration of
MLCP was 0.1 nM. Values are presented as a percentage of the average of three control reactions for each substrate without OA; three replicates of
each data point were assayed (n = 3), and error bars represent the standard deviations. The measured Ki of calyculin A for MLCP (from the
dephosphorylation of pC-ERMAD) was 0.17 ± 0.05 nM. As with the OA experiments in part (A), the increased IC50 with pCPI-17 (~30) reflects
competition of this substrate with calyculin; the nonlinear regression best-fit is Km = 0.36 ± 0.10 nM for the pCPI-17 dephosphorylation reaction.
DOI: 10.7554/eLife.24665.007
Figure 5. In vitro demonstration of the unfair competition mechanism for MLCP and pCPI-17. Enzyme assays
containing 0.25 nM MLCP and 1.4 mM C-ERMAD were performed at 30˚C for the indicated times, either in the
absence of CPI-17 (inverted triangles) or in the presence of 50 nM pCPI-17 (circles) or 50 nM thio(p)CPI-17
(squares). N = 3 for all data points; error bars represent standard errors of the mean. The data show that MLCP
must first dephosphorylate pCPI-17 before it can target the C-ERMAD substrate. The blue and green lines are
nonlinear regressions to the data in the absence of pCPI-17. The red line is the theoretical prediction based on the
previously measured pCPI-17/MLCP kinetic constants as described in Supplementary file 1.
DOI: 10.7554/eLife.24665.008
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For this reason, an accurate measure of the Km for the dephosphorylation of pCPI-17 by MLCP is
critically important. We estimated this value first from classical Michaelis-Menten experiments deter-
mining the initial velocity as a function of pCPI-17 concentration; this method indicated the Km to
be ~3 nM (Figure 3 and Figure 3—figure supplement 1). However, this value is likely a considerable
overestimate because, in samples with the requisite low concentrations of pCPI-17, substantial pro-
portions of the substrate were depleted during the reaction.
We therefore refined this estimate using a variant of a more accurate method developed for
tight-binding reactions (Takai et al., 1995; Williams et al., 2014) — by measuring the ability of the
pCPI-17 dephosphorylation reaction to compete with inhibition by okadaic acid (OA; Figure 4A) or
by calyculin A (Figure 4B) for the active site of MLCP. The first step was to measure accurately the
Kis of these inhibitors for MLCP using pMRLC, pC-ERMAD, and pMyBP substrates (blue, green, and
black lines, respectively in Figure 4). These Kis can be calculated from, and are close to, the IC50s
because these substrates have large Kms, and thus cannot compete with the inhibitors (see
Table 1. Phosphatase and substrate constants and concentrations.
Phosphatase
Substrate/
Inhibitor Constant Value Source figure or (reference)
pCPI-17 ([CPI-17]+[pCPI-17])phys 7 mM (Kitazawa and Kitazawa, 2012; Woodsome et al., 2001)
Phosphatase
Substrate/
Inhibitor Constant Value Source figure or (reference)
MLCP [MLCP]phys 1 mM (Alessi et al., 1992; Shirazi et al., 1994)
pCPI-17 Km 0.48 ± 0.03 nM Figure 4
kcat 0.06 ± 0.01 s
 1 Figure 2—figure supplement 1, Figures 3, 4 and 5
OA Ki 20 ± 2 nM Figure 4
calyculin A Ki 0.13–0.22 nM Figure 4
Phosphatase
Substrate/
Inhibitor Constant Value Source figure or (reference)
PP2A-B56a pCPI-17 Km 4.2 ± 0.5 mM Figure 6




Inhibitor Constant Value Source figure or (reference)
PPUa [PPU]aphys ~1.5 mM Figure 8
pCPI-17 Km 15 ± 2 mM Figure 7—figure supplement 2
kcat* 41 ± 6 s
 1 Figure 7, Figure 7—figure supplement 1 and Figure 8
OA Ki <0.5 nM Figure 7 and Figure 7—figure supplement 1
Phosphatase
Substrate/
Inhibitor Constant Value Source figure or (reference)




 1 Figure 7 and Figure 7—figure supplement 1
OA Ki ~450 nM Figure 7 and Figure 7—figure supplement 1
All parameters are at 30˚C.
phys: Physiological total (bound plus unbound) concentration; these values are computed using an estimated physiological total protein concentration
of 170 mg/ml (Wis´niewski et al., 2014).
PPUa is the PP2A-like component of PPU; it contributes 85% of the pCPI-17-directed PPU phosphatase activity. PPUb is the minor OA-resistant
component.
*Computed from kcat [PPU]
a/M/Km, [PPU]
a/M, and Km (see Table 2).
DOI: 10.7554/eLife.24665.009
Filter et al. eLife 2017;6:e24665. DOI: 10.7554/eLife.24665 9 of 27
Research article Biochemistry Cell Biology
Figure 2—figure supplement 1, Table 2, and Supplementary file 1). The experiments gave an OA
Ki of 20 ± 2 nM (n = 7), which is comparable with many published studies (Alessi et al., 1992;
Ishihara et al., 1989; Mitsui et al., 1992; Shirazi et al., 1994; Swingle et al., 2007); and a calyculin
A Ki range of 0.13–0.22 nM (n = 4), which is slightly lower than the value previously reported for inhi-
bition of the catalytic subunit of PP1 by this drug [0.4 nM (Swingle et al., 2007)]. The second step
was to determine the OA and calyculin A IC50s for the dephosphorylation of pCPI-17 by MLCP (red
lines in Figure 4), which were found to be more than one order-of-magnitude higher than those for
the other substrates. The reason is that the very high affinity of pCPI-17 for MLCP allows pCPI-17 to
compete effectively with the small molecule inhibitors; therefore, higher concentrations of the drugs
are needed to inhibit pCPI-17 dephosphorylation. Analysis of the combined results, as described in
Supplementary file 1, gave Km = 0.48 ± 0.03 nM [n = 8 (OA); n = 3 (calyculin A)] for the pCPI-17/
MLCP reaction. This more accurate determination, which is substantially lower than the estimate
from the substrate titration, corresponds with values at the low end of the range of previous IC50
measurements made using thio(p)CPI-17 [0.12–6 nM (Erdo˝di et al., 2003; Eto et al., 1995,
1997, 2000, 2004; Hayashi et al., 2001)].
The only precedent for a phosphatase reaction with a subnanomolar Km is that for the dephos-
phorylation of pEndos by PP2A-B55, the first example of the unfair competition mechanism
[(Williams et al., 2014); see Discussion]. In fact, very few if any other enzymatic reactions are
reported in the BRENDA enzyme database having Kms in the low nanomolar or even tens of nano-
molar ranges (Schomburg et al., 2013). Importantly, because to our knowledge all other measured
Kms of reactions between phosphatases and their ‘normal’ substrates are higher than 0.5 mM, we
can be certain that the pCPI-17 dephosphorylation observed in our experiments is catalyzed by
recombinant MLCP and not by any contaminating phosphatase.
Table 2. Additional phosphatase constants.
Phosphatase Substrate Constant Value Source figure or (reference)
MLCP Sphys
* ~15 Figure 8—figure supplement 2
pMyBP Km ~1.7 mM Figure 2—figure supplement 1
kcat ~0.18 s
 1 Figure 2—figure supplement 1
pC-ERMAD Km >2.5 mM Figure 2—figure supplement 1
kcat /Km 2.6 ± 0.03  10
 4 nM 1 s 1 Figure 2—figure supplement 1
pMRLC Km ~16 mM (Kawano et al., 1999)
Phosphatase Substrate Constant Value Source figure or (reference)
PPU Sphys
* ~24 Figure 8—figure supplement 2
pCPI-17 Km 15 ± 2 mM Figure 7—figure supplement 2
Km(0˚C) 14 ± 3 mM Figure 7—figure supplement 2
Phosphatase Substrate Constant Value Source figure or (reference)
PPUa pCPI-17 kcat (30˚C)/kcat (0˚C) 8.3 ± 0.8 Figure 7—figure supplement 1
kcat [PPU]
a/M/Km 0.024 ± 0.001 s
 1 ml mg 1 Figure 7 and Figure 7—figure supplement 1
[PPU]a/M 8.9 ± 0.9 pmol/mg Figure 8
Phosphatase Substrate Constant Value Source figure or (reference)
PPUb pCPI-17 kcat [PPU]
b/M/Km 0.0045 ± 0.0002 s
 1 ml mg 1 Figure 7 and Figure 7—figure supplement 1
All parameters are at 30˚C except as specified.
phys: Physiological total (bound plus unbound) concentration; these values are computed using an estimated physiological total protein concentration
of 170 mg/ml (Wis´niewski et al., 2014).
M: total extract protein concentration
S: Competition factor from other substrates (see Supplementary file 1)
DOI: 10.7554/eLife.24665.010
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pCPI-17 and MLCP interact through unfair competition
The low kcat and extremely low Km values for the interaction between MLCP and pCPI-17 dictate
that as long as pCPI-17 is available, it will occupy the active site of MLCP and prevent the enzyme
from dephosphorylating other substrates. However, when the kinases that phosphorylate pCPI-17
become inactivated, MLCP can dephosphorylate the bound pCPI-17 and the enzyme can then turn
its attention to other normal substrates such as the phosphorylated myosin regulatory light chain
and ERM proteins.
Figure 5 presents an in vitro demonstration of this principle. MLCP was incubated with 32P-
labelled pC-ERMAD substrate in the absence of pCPI-17 or in the presence of an excess of either
unlabeled pCPI-17 or thio(p)CPI-17. As expected, thio(p)CPI-17’s inhibition of MLCP remained con-
stant throughout the period of observation. In contrast, in the presence of pCPI-17, the rate of pC-
ERMAD dephosphorylation stayed low at early time points, when pCPI-17 is in excess of MLCP, but
it then began to increase, presumably when the concentration of pCPI-17 was reduced to the con-
centration of MLCP. The red curve in Figure 5 was calculated theoretically using the unfair competi-
tion model and the pCPI-17/MLCP kinetic constants calculated from Figures 3 and
4 (Supplementary file 1). In this example, because pCPI-17 was in >200 fold excess to MLCP, >50
min were required before the observed or calculated rate increase could take place. The good
agreement with the data demonstrates the quantitative accuracy of the model.
MLCP protects pCPI-17 from other phosphatases in mouse uterus
extracts
Other investigators have previously shown that cells contain enzymes other than MLCP that are
capable of dephosphorylating pCPI-17 (Eto and Brautigan, 2012; Eto et al., 2004; Hersch et al.,
2004; Kitazawa, 2010; Obara et al., 2010; Takizawa et al., 2002). We believe that the majority of
this PPU activity is due to forms of PP2A-like enzymes, including various isoforms of PP2A, as well as
the closely related PP4 and PP6, for two reasons:
First, we verified that at least one PP2A-containing enzyme, PP2A-B56a, indeed efficiently
releases phosphate from pCPI-17 (Figure 6) with kcat ~30 s
 1 (Table 1). PP2A-B56a thus dephos-
phorylates pCPI-17 about 500 times faster than does MLCP when the pCPI-17 substrate is
Figure 6. Kinetic analysis of the dephosphorylation of pCPI-17 by PP2A-B56a, a candidate PPU enzyme. (A). Linearity of assay employing PP2A-B56a
enzyme (at 0.25 nM); the concentration of pCPI-17 was 1 mM. (B) Velocity of the dephosphorylation of pCPI-17 by 0.1 nM PP2A-B56a as a function of the
concentration of the pCPI-17 substrate. Reactions were performed for 1 min at 30˚C in a volume of 4 mL. The data were analyzed by Prism 6 software as
in Figure 4, giving Km = 4.2 ± 0.5 mM and kcat = 29 ± 2 s
 1.
DOI: 10.7554/eLife.24665.011
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saturating. However, the Michaelis constant (Km) for the dephosphorylation of pCPI-17 by this PP2A
holoenzyme is in the micromolar range, reflecting an affinity for pCPI-17 that is three orders-of-mag-
nitude lower than that of MLCP.
Second, we examined the phosphatase activity directed against pCPI-17 in highly diluted extracts
of mouse uterus, a smooth muscle tissue enriched for MLCP (Aguilar and Mitchell, 2010). In these
experiments (Figure 7 and Figure 7—figure supplement 1), the pCPI-17 concentration was much
greater than the estimated MLCP concentration, so we expected that there would be little protec-
tion and that most dephosphorylation would be due to PPU enzymes. Quantitative analysis of these
data and of the results that will be presented in Figure 8 below showed that ~85% of the activity
was sensitive to subnanomolar OA with Km ~ 15 ± 2 mM and kcat = 41 ± 6 s
 1 (n = 3), consistent with
the known properties of PP2A-like enzymes (Prickett and Brautigan, 2006; Swingle et al., 2007)
and of the purified PP2A holoenzyme example measured in Figure 6 (see Supplementary file 1 for
the quantitative analysis). We ascribe the residual phosphatase activity (with OA IC50 ~ 500 mM) to
other PPU phosphatases more resistant to the OA drug.
The observation that the Kms for dephosphorylation of pCPI-17 by PPU enzymes are at least three
orders-of-magnitude higher than the Km for dephosphorylation of pCPI-17 by MLCP (Table 1)
implies that MLCP will prevent PPU from accessing pCPI-17 when MLCP is in excess of the substrate.
In this situation, essentially all pCPI-17 dephosphorylation must be catalyzed by MLCP. Only when
pCPI-17 is in excess of MLCP will any appreciable amount of the substrate be available to other
phosphatases.
We tested this inference using concentrated mouse uterus extracts that more closely approximate
the intracellular situation. These experiments compared the kinetic properties of the phosphatases
responsible for pCPI-17 dephosphorylation and their sensitivities to OA-inhibition when the pCPI-17
concentration was either much greater than, or much smaller than, the MLCP concentration
Figure 7. Okadaic acid inhibition of the dephosphorylation of pCPI-17 by dilute mouse uterus extracts. Mouse
uterus extracts at a dilution of 1:556 were prepared as described in Materials and methods and incubated at 30˚C
for 45 s with 687 nM 32P-labeled pCPI-17 plus the indicated concentrations of okadaic acid (OA). The mean
phosphate released (with standard deviations; n = 3) is shown as a percentage of release in the absence of OA.
Since the pCPI-17 concentration is much greater than the MLCP concentration at these dilutions, essentially all
dephosphorylation is due to PP2A and other non-MLCP phosphatases (collectively called PPU).
DOI: 10.7554/eLife.24665.012
The following figure supplements are available for figure 7:
Figure supplement 1. Okadaic acid inhibition of the dephosphorylation of pCPI-17 by dilute mouse uterus
extracts.
DOI: 10.7554/eLife.24665.013
Figure supplement 2. Kinetic analysis of the dephosphorylation of pCPI-17 by PPU.
DOI: 10.7554/eLife.24665.014
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Figure 8. Sequestration of pCPI-17 by MLCP in concentrated mouse uterus extracts. Undiluted mouse uterus extracts (~14 mg/ml) were assayed for
phosphatase activity using 32P-labeled pCPI-17 (0˚C) or pC-ERMAD (30˚C) substrates at the concentrations shown with the indicated concentrations of
OA. Results and standard deviations (n = 3) are given as a percentage of the average value for each substrate dilution in the absence of OA (n = 3). As
described in Results and Supplementary file 1, the increase in IC50 at low pCPI-17 concentrations (i.e. 0.01 or 0.09 mM) results from sequestration of
Figure 8 continued on next page
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(Figure 8). Based on previous measurements of the physiological MLCP concentration (Alessi et al.,
1992; Shirazi et al., 1994) and accounting for extract dilution, the MLCP concentration in these
extracts was ~0.08 mM. We expect that when the pCPI-17 concentration is in great excess (i.e., 1.35
mM in Figure 8), almost all its dephosphorylation will be due to PP2A-like enzymes rather than
MLCP, given their much greater kcats. Because OA inhibits these PPU phosphatases with subnano-
molar Kis, the IC50 is determined by, and allows us to compute, the PP2A-like PPU concentration in
the extract [and by extension, the concentration of these enzymes in smooth muscle tissue (Table 1
and Supplementary file 1)]. In contrast, when the pCPI-17 concentration is commensurate with, or
lower than, the MLCP concentration (i.e. [pCPI-17]=0.09 mM or 0.01 mM, respectively), unfair compe-
tition predicts that most pCPI-17 will be sequestered by MLCP and that the IC50 will be large
because a high OA concentration is needed to compete with the tight pCPI-17/MLCP binding. The
results shown in Figure 8 conform to these predictions. In particular, note that the IC50 for OA
increases roughly 10 as the pCPI-17 concentration decreases from 1.35 mM to 0.01 mM because
the identity of the relevant pCPI-17 phosphatase changes from PPU to MLCP.
The dephosphorylation of pC-ERMAD serves as a control in Figure 8. In the concentrated
extracts, more than 75% of the activity against this substrate is due to PP1-containing enzymes
[mostly, but not exclusively, MLCP; see Figure 8—figure supplement 1 and (Eto et al., 2000;
Fukata et al., 1998; Liu et al., 2015)]. Because the Km for the dephosphorylation of pC-ERMAD by
MLCP (>2.5 mM; Figure 2—figure supplement 1D and Table 2) is much higher than the Ki for OA
(~20 nM; Figure 4A and Table 2), pC-ERMAD cannot compete effectively with OA for the active site
of MLCP and other PP1-containing holoenzymes. We therefore anticipated that the OA IC50 for the
dephosphorylation of pC-ERMAD in concentrated uterus extracts should be unaffected by varying
the substrate concentration. Again, the results shown in Figure 8 concur with this prediction; the
OA IC50 is virtually identical when the pC-ERMAD concentration is 0.2 mM and when it is 2 mM.
The absolute rate of dephosphorylation at the lowest pCPI-17 concentration in the concentrated
extract experiment provides another confirmation that MLCP, rather than other PPU phosphatases,
dephosphorylates pCPI-17 when MLCP is in excess. As just explained, when pCPI-17 is at 0.01 mM
virtually all it is sequestered by binding; therefore, the enzyme-substrate complex concentration is
known (i.e. 0.01 mM) and we can determine the kcat of the responsible phosphatase to be ~0.007
s 1. This result is in excellent agreement with ~0.008 s 1, the mean kcat measured in vitro for purified
recombinant MLCP (Figures 2–5) after adjustment for the 0˚C reaction temperature that was
required for technical reasons (see Figure 7—figure supplement 2 and Supplementary file 1). The
close fit between these two kcat values provides further support for the unfair competition model by
identifying MLCP as the enzyme ultimately responsible for the dephosphorylation of sequestered
pCPI-17 in concentrated extracts.
pCPI-17 dephosphorylation by MLCP is crucial to timely MLCP
reactivation
We next compared the unfair competition model with current ideas positing pCPI-17 dephosphory-
lation by PPU (Eto and Brautigan, 2012; Eto et al., 2004; Hersch et al., 2004; Kitazawa, 2010;
Obara et al., 2010; Takizawa et al., 2002) in their abilities to explain the physiological experiments
of Kitazawa et al. (2009) investigating the temporal responses of contracted rabbit femoral artery
to sodium nitroprusside (SNP), a nitric oxide (NO) donor that induces vasodilation by partially deacti-
vating the kinase(s) acting on pCPI-17. Figure 9 shows their published measurements of the tempo-
ral changes in CPI-17 and myosin regulatory light-chain (MRLC) phosphorylation following
Figure 8 continued
the substrate by MLCP. In contrast, the IC50 for dephosphorylation of pC-ERMAD is insensitive to its concentration because only one enzyme, MLCP, is
primarily responsible and there is no sequestration.
DOI: 10.7554/eLife.24665.015
The following figure supplements are available for figure 8:
Figure supplement 1. Dephosphorylation of pC-ERMAD by mouse uterus extracts.
DOI: 10.7554/eLife.24665.016
Figure supplement 2. Determination of the ‘strength’ of competing phosphatase substrates and inhibitors in mouse uterus extracts.
DOI: 10.7554/eLife.24665.017
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application of SNP to the tissue, along with the computational predictions under three scenarios for
the phosphatases acting on pCPI-17: (i) PPU-alone (the current model, but accounting for the
sequestration of pCPI-17 by MLCP), (ii) MLCP-alone, and (iii) both MLCP and PPU (unfair competi-
tion). To compute the simulations, we used the data from Kitazawa et al. (2009) to determine the
pCPI-17-directed kinase and MLCP activities in the initial (vasoconstricted) and final (vasodilated)
states, the pCPI-17/MLCP and pCPI-17/PPU parameters determined in this study (Tables 1 and
2), and the results from Figure 8—figure supplement 2 that allowed us to account for the seques-
tration of both MLCP and PPU by other cellular substrates. From the change in MRLC phosphoryla-
tion, we inferred that MLCP activity increased ~2.4-fold following the addition of SNP, which is close
to the ~3-fold increase measured by direct enzyme assays (Etter et al., 2001) in a system similar to
that used by Kitazawa et al. (2009). The shaded regions in Figure 9 show the variation in the pre-
dictions of the various models over the potential range of MLCP concentrations (0.7–2 mM) deter-
mined from earlier studies in various smooth muscle tissues (Alessi et al., 1992; Shirazi et al.,
1994). This variation is noticeable only in the PPU-alone model that ignores MLCP dephosphoryla-
tion of pCPI-17 (top row in Figure 9). In addition, varying the other relevant parameters over their
Figure 9. Comparing models for aorta relaxation upon application of vasodilator. Black points with error bars reproduce data from Figure 4 in
(Kitazawa et al., 2009) describing the temporal variation in the levels of (A) CPI-17 and (C) MRLC phosphorylation following the application of the
vasodilator sodium nitroprusside to rabbit aorta at t = 0. Red lines show theoretical predictions (see Supplementary file 1) under three scenarios: top,
PPU alone (current model, but allowing for sequestration of pCPI-17 by MLCP); middle, MLCP alone; and bottom, MLCP and PPU (unfair competition).
(B) The computed relative MLCP activity on substrates other than pCPI-17. Shaded regions (which are barely discernable in the bottom two rows)
indicate the variation in the predictions over the potential range of aortic MLCP concentration.
DOI: 10.7554/eLife.24665.018
The following figure supplement is available for figure 9:
Figure supplement 1. Effect of ROCK thiophosphorylation on MLCP activity.
DOI: 10.7554/eLife.24665.019
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error ranges (Table 1) was found to have minor effect on any of the curves (not shown; see
Supplementary file 1).
The major lesson of the modeling shown in Figure 9 is that smooth muscle relaxation cannot take
place with its observed rapid kinetics if MLCP does not participate in pCPI-17 dephosphorylation.
The half-life for pCPI-17 dephosphorylation in the absence of MLCP activity (column A, top) is ~10
longer than the experimental ~10 s. As a result, the reactivation of MLCP is very slow (column B,
top), as is the consequent dephosphorylation of MRLC (column C, top). The fit of this PPU-alone
model to the published results is poor. On the other hand, an unfair competition system in which
MLCP dephosphorylates pCPI-17 with the kinetic parameters we determined provides a good fit to
the published data (bottom row). Interestingly, the rapidity of these events is virtually unaffected
whether the system has no PPU activity or the substantial PPU activity indicated by our measure-
ments (compare the middle and bottom rows in Figure 9). This outcome emerges because the con-
tracted muscle starts out with MLCP in small excess of pCPI-17, so essentially all pCPI-17 is bound
to MLCP, and the half-lives for pCPI-17 and MRLC dephosphorylations are determined almost exclu-
sively by the kcat for the dephosphorylation of pCPI-17 by MLCP. That is, even though the tissue is
well provisioned with PPU enzymes, they cannot access the MLCP-bound pCPI-17. We conclude that
MLCP dephosphorylation of pCPI-17 is both necessary and sufficient for its reactivation during
vasodilation.
pCPI-17 dephosphorylation by MLCP is not importantly affected by
physiological levels of MYPT1 inhibitory phosphorylation
The MYPT1 subunit of MLCP is subject to inhibitory phosphorylations at Thr696 and Thr853. The phos-
phorylation at Thr696 inhibits enzyme activity, while that at Thr853 disrupts association of MLCP with
its myosin substrate (Khasnis et al., 2014; Velasco et al., 2002). The kinase ROCK can phosphory-
late both sites efficiently in vitro (Feng et al., 1999a, 1999b; Kawano et al., 1999;
MacDonald et al., 2001), but in vivo other kinases such as ZIPK, ILK, and PAK may also target
pThr696 [reviewed in (Grassie et al., 2011)]. In most smooth muscles, the levels of Thr696 phosphory-
lation are high even in the relaxed condition, approaching 50% site occupancy. While most studies
have concluded that pThr696 levels are constitutive (Chen et al., 2015; Kitazawa et al., 2003;
Niiro et al., 2003; Tsai et al., 2014; Wilson et al., 2005), some have reported modest increases in
particular tissues stimulated to contract by certain agonists (Bhetwal et al., 2013; Lubomirov et al.,
2006). One could thus argue that MLCP cannot be the enzyme that dephosphorylates pCPI-17
because MLCP in contracted tissue is inactivated by MYPT1 phosphorylation, particularly at Thr696.
These considerations prompted us to determine whether inhibition of MLCP by Thr696 phosphor-
ylation might significantly affect the physiological process modeled in Figure 9. To this end, we thio-
phosphorylated MLCP with a molar excess of ROCK, and assayed the effects on pCPI-17
dephosphorylation (Figure 9—figure supplement 1). Because the amounts of MLCP used were too
small to obtain reliable direct measurements of its thiophosphorylation level, we confirmed that our
treatment inhibited its activity to at least the physiological extent using pC-ERMAD as a control sub-
strate. ROCK phosphorylation of MLCP reduced MLCP’s dephosphorylation of pC-ERMAD by ~70%,
which is essentially the same as the maximum decrease in MLCP phosphatase activity observed in
previous in vitro studies (Feng et al., 1999a, 1999b; Ichikawa et al., 1996; Khasnis et al., 2014;
Mura´nyi et al., 2005, Mura´nyi et al., 2002; Wooldridge et al., 2004). More importantly, this con-
trol establishes that in our experiments, a larger fraction of MLCP was inhibited by Thr696 (thio)phos-
phorylation than in the physiological situation. Therefore, finding that the same preparations of thio
(p)Thr696 MLCP displayed activities against pCPI-17 that were reduced only ~20% relative to the
untreated enzyme (Figure 9—figure supplement 1) provides an upper bound on the physiological
inhibition of the MLCP-mediated pCPI-17 dephosphorylation rate. This small level of inhibition does
not significantly affect the physiological modeling of Figure 9.
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Discussion
MLCP is the enzyme primarily responsible for physiologically significant
pCPI-17 dephosphorylation
Previous studies concluded that the dephosphorylation of pCPI-17 is accomplished by phosphatases
other than MLCP [other PP1 holoenzymes, PP2A, and PP2C (Eto and Brautigan, 2012; Eto et al.,
2004; Hersch et al., 2004; Kitazawa, 2010; Obara et al., 2010; Takizawa et al., 2002)] that can
react with pCPI-17 much faster than MLCP. However, these studies failed to account adequately for
the shielding of pCPI-17 from PPU enzymes when MLCP and pCPI-17 are present at physiological
protein concentrations. This shielding results from the extremely low Km (0.48 ± 0.03 nM) of the
pCPI-17/MLCP interaction.
This very low Km reflects the combined effects of a very high second-order association rate kon
that must be in excess of 1.25  108 M 1 s 1, and slow unbinding (koff) and catalytic (kcat) rates.
Such high association rates have been observed previously but are quite rare (Archakov et al.,
2003; Moal and Bates, 2012). The high kon likely benefits from electrostatic MLCP-pThr
38 interac-
tions (Eto et al., 2007; Schreiber et al., 2009). Moreover, kon is further increased while koff is
decreased by the structural rigidity of pCPI-17 that results from its phosphorylation at Thr38
(Eto et al., 2007). This rigidity increases the fraction of ligands that are in the bound conformational
ensemble even before binding, and therefore reduces the loss of conformational entropy upon bind-
ing and the gain upon unbinding (Archakov et al., 2003; Moal and Bates, 2012). In addition, the
structural rigidity of pCPI-17 inhibits its hydrolysis (Eto et al., 2007), accounting for the low kcat and
decreasing the Kmfurther [since Km = (koff + kcat)/kon]. Consistent with the importance of pCPI-17
rigidity, point mutation of residues nearby Thr38 that should result in increased flexibility coordi-
nately increase both the IC50 (up to 5000) of MLCP inhibition and the kcat of pCPI-17 dephosphory-
lation (up to ~7.5 s 1) (Hayashi et al., 2001).
Unfair competition is necessary and sufficient for highly responsive
regulation of CPI-17 phosphorylation
Applied to smooth muscle contraction/relaxation, our hypothesis of unfair competition posits that
MLCP and pCPI-17 mutually sequester each other from other molecules during contraction, when
sufficient CPI-17-directed kinase activity exists to maintain enough pCPI-17 to bind most MLCP.
When the rate of phosphorylation decreases during relaxation (due to downregulation of PKC and
other kinases targeting the pThr38 site of CPI-17), MLCP is able to restart its own action against its
normal substrates by dephosphorylating pCPI-17.
We demonstrated the various facets of this hypothesis in vitro using purified components (Fig-
ures 2–6), using crude extracts (Figure 8), and by in silico modeling (Figures 5 and 9). We showed
that unfair competition is necessary for timely reactivation of myosin phosphatase because mecha-
nisms that depend solely on the dissociation of pCPI-17 from MLCP would be far too slow (Figure 9).
In fact, the modeling in Figure 9 substantially underestimates the importance of unfair competition
for the rapidity of smooth muscle relaxation because the MYPT1 regulatory subunit tethers the phos-
phatase to myosin filaments [reviewed by (Khasnis et al., 2014)]. In the vicinity of these filaments,
the ratio of MLCP relative to PPU enzymes would be much higher than the cellular average used in
the calculations.
The total CPI-17 concentration is large [~7 mM (Kitazawa and Kitazawa, 2012;
Woodsome et al., 2001)], but our calculations using the data from Kitazawa et al. (2009) imply
that only the relatively small fraction that is bound to MLCP [~1 mM (Alessi et al., 1992;
Shibata et al., 2015)] is phosphorylated. This conclusion is supported by recent experimental stud-
ies. First, only a fraction of total CPI-17 is phosphorylated even in contracted arteries; the amount of
pCPI-17 roughly corresponds to the concentration of MLCP (Kitazawa and Kitazawa, 2012). Sec-
ond, in mice whose arteries contain a conditional knockout of MYPT1, the levels of pCPI-17 present
after norepinephrine stimulation are considerably lower than those in stimulated wild-type animals,
even though the total concentration of CPI-17 is unchanged (Qiao et al., 2014; Tsai et al., 2014).
Our interpretation of this latter result is that the MYPT1 knockout exposed pCPI-17 to other phos-
phatases (PPUs) that dephosphorylated it rapidly.
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We therefore envision that the role of PPU phosphatases in this mode of MLCP regulation is sim-
ply to ensure that cells always have little free pCPI-17 that is not bound by MLCP. The contractile
apparatus thus can respond quickly and efficiently to reduction in the activities of CPI-17-targeting
kinases such as PKC because, upon addition of a vasodilator, each MLCP molecule needs only to
dephosphorylate the pCPI-17 molecule with which it is already associated. This idea explains why
the speeds of pCPI-17 dephosphorylation and MLCP reactivation predicted by our model are virtu-
ally unaffected by PPU activity during the transition to vasodilation (Figure 9, middle and bottom
rows). A curious corollary of this concept is that MLCP, the enzyme inhibited by pCPI-17, is ulti-
mately responsible for protecting its inhibitor from the action of other phosphatases. If MLCP did
not have this protective function, the intracellular concentration of pCPI-17 even during contraction
would likely be too low to be of much significance in determining muscle tension.
If only the small fraction of CPI-17 that is phosphorylated is of relevance to MLCP inhibition, why
do smooth muscle cells have such high levels of total CPI-17 [~7 mM (Kitazawa and Kitazawa, 2012;
Woodsome et al., 2001)]? We suggest that high total CPI-17 may be needed to maintain even the
small amount of pCPI-17 needed for inhibition. The CPI-17 kinases (e.g. PKC and ROCK) need to
generate pCPI-17 at a rate sufficient to counteract the pCPI-17 phosphatases (MLCP and PPU). A
requirement for high total CPI-17 may be particularly acute because most CPI-17 is cytosolic, while
activated PKC and ROCK go to the plasma membrane upon activation (Gong et al., 1997;
Haller et al., 1990; Woodsome et al., 2001).
Downregulation of CPI-17-directed kinases is likely sufficient to explain
the rapid phase of vasodilation
The unfair competition model quantitatively explains SNP’s near-term (within 30 s) experimentally
measured effects on CPI-17 and MRLC phosphorylation (Kitazawa et al., 2009) as consequences of
a single event: an approximately 50% decrease in the activity of the kinases targeting CPI-17 Thr38.
Although we do not know of studies directly measuring the activities of these enzymes in response
to vasodilator administration, the same report established the importance of their downregulation
under the conditions employed, because pCPI-17 levels did not decrease after SNP addition in the
presence of phorbol esters that artificially ‘clamp’ the activities of these kinases at high levels
(Kitazawa et al., 2009).
The major kinases responsible for Thr38 phosphorylation are Ca2+-dependent PKC, Ca2+-indepen-
dent PKC (Eto et al., 2001), and Rho-associated kinase [ROCK; (Kitazawa et al., 2000)]. We believe
that inactivation of Ca2+-dependent PKC is of greatest consequence here because a straightforward
mechanism could cut its activity significantly within a few seconds [reviewed by (Kitazawa et al.,
2009; Somlyo and Somlyo, 2003)]. Nitric oxide (NO) released from SNP stimulates guanylyl cyclase
to synthesize cGMP, which activates Protein kinase G (PKG). Phosphorylation of various PKG targets
indirectly lowers levels of cytoplasmic Ca2+, a cofactor for several forms of PKC. Because Ca2+ binds
PKC cooperatively (the Hill coefficient is between 2 and more than 8, depending on conditions),
small decreases in the levels of Ca2+ can potentially be amplified into much larger decreases of PKC
activity (Egea-Jime´nez et al., 2013). PKG can also downregulate ROCK, the other major CPI-17
Thr38 kinase, by phosphorylating and thus inactivating RhoA (Sauzeau et al., 2000), although these
changes in ROCK appear to be too slow to contribute much to the near-term events studied here
(Kitazawa et al., 2009).
Some previous studies [e.g. (Bonnevier and Arner, 2004)] have posited that the addition of vaso-
dilators such as SNP not only rapidly downregulates the kinases targeting CPI-17, but also upregu-
lates one or more countering PPU phosphatases. Our identification of MLCP as the key physiological
phosphatase for pCPI-17 brings this supposition into question. First, as discussed above, a PPU
phosphatase would need to have a Km in the nanomolar or lower range to be able to compete with
MLCP. Second, our quantitative analysis shows that a two-fold downregulation of CPI-17-targeting
kinases following SNP addition is sufficient to explain the rapid loss of CPI-17 phosphorylation due
to dephosphorylation by MLCP (see Supplementary file 1 for details). The predicted half-life of this
process is t1/2 = log 2/kcat » 12 s, which is in excellent agreement with experiment (Kitazawa et al.,
2009). Any additional processes that significantly increased this rate of CPI-17 dephosphorylation
would not be consistent with the physiological observations.
Although we doubt that NO-induced vasodilation involves significant increases in PPU enzyme
activities, we cannot exclude that events other than pCPI-17 dephosphorylation might help
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upregulate MLCP. One candidate is the phosphorylation of MYPT1 by PKG, which has been
observed to increase considerably during the first minute after exposure to SNP (Kitazawa et al.,
2009). PKG can phosphorylate MYPT1 at several sites, including Ser668, Ser692, Ser695, and Ser852
(Wooldridge et al., 2004; Yuen et al., 2011). The phosphorylations of two of these sites (Ser695 and
Ser852) appear not to affect MLCP activity directly, but instead prevent inhibitory Rho kinase-medi-
ated phosphorylations (Nakamura et al., 2007; Wooldridge et al., 2004). However, after SNP treat-
ment, these Rho kinase-mediated phosphorylations are removed too slowly to contribute to rapid
MLCP activation within 15 s of SNP addition (Kitazawa et al., 2009). It remains possible that PKG-
mediated phosphorylations of certain isoforms of MYPT1 at the other two sites (Ser668 and/or
Ser852) might participate in MLCP activation (Yuen et al., 2014), but our results suggest that any
such contributions are relatively modest. On its own, the observed change in pCPI-17 levels after
SNP administration can account for the increase in MLCP activity during vasodilation.
Concomitant with the rapid decrease in pCPI-17 levels and the rapid activation of MLCP after
vasodilator addition is the key downstream physiological readout: the rapid decrease in myosin reg-
ulatory light chain (MRLC) phosphorylation (Kitazawa et al., 2009). In theory, lower levels of pMRLC
could be achieved not only by upregulating MLCP, as detailed in this study, but also by inactivating
myosin light chain kinase (MLCK). Given that SNP treatment reduces Ca2+ levels and thus potentially
can downregulate MLCK, it is perhaps surprising that the simulation in Figure 9 was successful even
though it assumed MLCK function was constant. Perhaps, in the experimental system of
Kitazawa et al. (2009) analyzed in Figure 9, the SNP-induced decreases in the activity of CPI-17-tar-
geting kinases were more important than any decrease in MLCK activity, which was likely at a very
low basal level prior to SNP addition (Dimopoulos et al., 2007; Isotani et al., 2004). We note that
even if MLCK inactivation plays a more significant role in determining MRLC phosphorylation during
vasodilation than assumed by our model, no known pathway exists through which MLCK downregu-
lation could impact the pCPI-17 levels or MLCP activities analyzed in Figure 9.
Unfair competition may provide a general mechanism for the regulation
of PPP phosphatases by AGC kinases
We previously showed that unfair competition is central to another important physiological situation:
cell cycle transitions into and out of mitosis (Williams et al., 2014). During M phase, the PP2A-B55
phosphatase is inactivated by a mechanism involving small proteins of the Endosulfine/ARPP19 fam-
ily (hereafter, Endos); these become PP2A-B55 inhibitors after their phosphorylation by the Great-
wall kinase (Gwl) following the latter’s activation by Cdk1-Cyclin B (Blake-Hodek et al., 2012;
Castilho et al., 2009; Gharbi-Ayachi et al., 2010; Mochida, 2014; Mochida et al., 2010;
Williams et al., 2014; Yu et al., 2006). Following inactivation of Cdk1-Cycliin B and Gwl at M phase
exit, PP2A-B55 rapidly dephosphorylates pEndos and thus reactivates itself to attack mitosis-specific
phosphosites. The dephosphorylation of pEndos by PP2A-B55 is both required and sufficient to
account for the rapidity of pEndos dephosphorylation and of PP2A-B55 reactivation during M phase
exit (Williams et al., 2014).
Unfair competition requires that the inhibitor/substrate bind very tightly to the active site and be
dephosphorylated there only slowly. These requirements hold for the dephosphorylations both of
pCPI-17 by MLCP (during muscle relaxation) and of pEndos by PP2A-B55 (during M phase exit); in
fact, the kinetic constants are nearly identical in the two cases (Km = 0.48 ± 0.03 nM and 0.47 ±
0.014 nM, respectively; kcat = 0.06 ± 0.01 s
 1 and 0.02–0.07 s 1, respectively). Of greatest interest,
the Kms are both subnanomolar; that is, lower by 2–3 orders of magnitude than that for any previ-
ously described dephosphorylation reaction.
Unfair competition provides an economical regulatory mechanism during changing cellular condi-
tions: Only the upstream kinase that phosphorylates the inhibitor needs to be controlled; the sequel
is an automatic consequence of the kinetic properties of the phosphatase to which the inhibitor is
bound. No other steps that would introduce complexity to the system, such as allosteric control of a
putative PPU enzyme, are needed.
Moreover, if such additional complexity is to be avoided, then unfair competition is likely the inev-
itable consequence of the well-known fact that PPP catalytic subunits can target a wide variety of
substrates. Thus, in the cell, many molecules are competing for the catalytic sites, and we can esti-
mate experimentally the magnitude of this competition (Figure 8—figure supplement 2; see
Supplementary file 1). To inhibit an enzyme’s ability to dephosphorylate a large number of
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potential substrates, which will have a large aggregate concentration, a competitive inhibitor (e.g.
pCPI-17 or pEndos) must have an extremely low Km for its target phosphatase (e.g. MLCP or PP2A-
B55). Given the necessity for such very strong affinity between enzyme and inhibitor, inactivation of
the inhibitor by the same enzyme provides the only pathway that allows cells and tissues to reset
their state rapidly (e.g. during muscle relaxation or M phase exit).
These two examples of unfair competition involve processes with different fundamental require-
ments. Cell cycle transitions must operate much like on-off switches: Cells can be either in interphase
or M phase, but cannot remain in an intermediate state. On the other hand, smooth muscle contrac-
tility must be regulated like a rheostat: Arteries often must be able to respond in a graded fashion
to changing mixtures of agonists and vasodilators. How can phosphatase modules, both governed
by unfair competition, participate in processes with such disparate needs? We suggest that the
explanation lies in the presence (Endos, M phase) or absence (CPI-17, vasoconstriction) of positive
feedback mechanisms that can convert a modest change in the activity of an upstream regulatory
kinase into a discrete ‘on-off’ signal.
At the beginning of M phase, positive feedback increases Gwl activity by two pathways. The first
mechanism is direct: Partially phosphorylated Gwl phosphorylates some pEndos which partially
inhibits PP2A-B55; this further increases Gwl activity, presumably by decreasing the rate of Gwl
dephosphorylation (Mochida et al., 2016). The other mechanism is indirect: pEndos inhibition of
PP2A-B55 decreases the dephosphorylation of Cdc25 and Myt1/Wee1 by PP2A-B55, promoting the
Cdk1 autoregulatory loop and consequently the activation of Gwl (Blake-Hodek et al., 2012;
Williams et al., 2014; Yu et al., 2006) by raising the Gwl phosphorylation rate. Positive feedback
also probably occurs at the end of M phase, when Gwl becomes dephosphorylated and turned ‘off’.
Although PP1 (Heim et al., 2015; Ma et al., 2016; Mochida, 2015; Rogers et al., 2016) and per-
haps other enzymes (Della Monica et al., 2015) initiate Gwl inactivation, PP2A-B55 also likely plays
a role in completing and then maintaining Gwl dephosphorylation (Mochida et al., 2016;
Yamamoto et al., 2011).
In contrast, we know of no data indicating that pCPI-17 influences the activity of PKC or other
upstream kinases that govern CPI-17 phosphorylation. Therefore, no feedback exists, consistent with
our analysis in Figure 9 indicating that CPI-17 kinases are not turned off completely even in the pres-
ence of vasodilators. Our calculations instead indicate that, under the experimental conditions, SNP-
treated smooth muscles retain a basal CPI-17 kinase activity that is about one-half that of the con-
tracted state (see Supplementary file 1). In other words, regulation of these kinases is graded rather
than discontinuous.
It is striking that the kinases most likely to be involved in the phosphorylation of CPI-17 (PKC and
ROCK) and Endos (Gwl) are all members of the AGC kinase family [reviewed in (Arencibia et al.,
2013)]. This fact suggests that early in the evolution of the eukaryotic lineage, a prototypic AGC
kinase phosphorylated an inhibitor of a prototypic PPP phosphatase and that the inhibitor and phos-
phatase interacted according to the logic of unfair competition. An intriguing speculation is that
many of the other PPP holoenzymes that exist in eukaryotic cells eventually will be found to be regu-
lated in similar ways by other AGC kinase family members.
Materials and methods
Cell lines
HEK293 CRL-1573 cells were obtained from the American Type Culture Collection (Manassas, VA).
The identity of these cells was not subsequently authenticated because the cells were only used for
the purification of reagents rather than as experimental materials. The cells were grown in Dulbec-
co’s Modified Eagle Medium +10% Fetal Bovine Serum (Invitrogen, ThermoFisher Scientific) in the
presence of 100 units/ml of penicillin and 100 mg/ml of streptomycin and a 1:100 dilution of the anti-
mycotic Fungizone (Gibco, ThermoFisher Scientific).
Purification of MLCP and other phosphatases
Human MYPT1 (PPP1R12A) cDNA was obtained from GE-Dharmacon (clone accession number
BC111752). An N-terminal FLAG-peptide was fused to the MYPT1 coding sequence and cloned into
the mammalian expression vector pcDNA5. pcDNA5-TO vector alone (Invitrogen), pcDNA5-TO/
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FLAG-B56a, and pcDNA5-TO/FLAG-MYPT1 plasmid DNAs were transfected into HEK293 CRL-1573
cells using Lipofectamine 2000 (Invitrogen) using the manufacturer’s protocols and harvested after
72 hr. Holoenzymes were isolated according to Adams and Wadzinski (2007); Williams et al.,
2014). Purified complexes were resolved by SDS-PAGE and visualized by silver staining. Protein con-
centrations were estimated by comparison to BSA standards. The compositions of the holoenzymes
were verified by Western blot.
Substrate purification and labeling
Human CPI-17 was cloned into a modified pGEX vector, creating an N-terminally 6-His fusion. We
used the Stratagene Quik-change kit to create a Ser12-to-Ala12 mutation in the recombinant CPI-17.
The Ala12 mutant was phosphorylated to ~80% of the wild-type level, suggesting that Ser12 in wild-
type CPI-17 was only minimally phosphorylated in vitro by the method that will be described below.
In agreement, subsequent classical Michaelis-Menten experiments established that the Ala12 mutant
and the wild-type proteins were dephosphorylated by MLCP with the same Kms and kcats, to
within ~15% (n = 2). These two CPI-17 fusions (wild-type or the Ala12 mutant) were subsequently
transformed into E. coli BL21-Gold(DE3) cells (Agilent Technologies, catalog #230132). Freshly trans-
formed cells were grown to an OD600 of 0.6 in 2 yeast tryptone broth supplemented with 100 mg/
ml of ampicillin, then induced with 1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) for 4 hr at
37˚C.
Cells were harvested by centrifugation and stored at  70˚C. Cells were lysed in 20 ml of lysis
buffer (50 mM Tris-HCl, pH8.0; 500 mM NaCl; 5 mM imidazole, 5% glycerol, 0.025% Tween20, 5
mM b-mercaptoethanol) supplemented with Complete EDTA-free protease inhibitor (Roche) and
with 300 mg/ml of lysozyme, followed by sonication to complete lysis. Cleared lysates were bound to
Ni-NTA Agarose beads (Qiagen) overnight at 4˚C, then transferred to a column and washed with
250 mL of wash buffer (10 mM Tris-HCl, pH 8.0; 500 mM NaCl; 15 mM imidazole, 40 mM glycine,
0.025% Tween20, 5 mM b-mercaptoethanol, and 5% glycerol). CPI-17 was then eluted in 10 mM
Tris-HCl, pH 8.0; 500 mM NaCl, 200 mM imidazole, 0.025% Tween20, 5 mM b-mercaptoethanol,
and 5% glycerol. Eluted protein was concentrated and exchanged into storage buffer (25 mM Tris-
HCl, pH 8.0; 500 mM NaCl, 0.025% Tween20, 5 mM b-mercaptoethanol, and 5% glycerol) using
Amicon Ultra-4 centrifugal filters with a 3 K molecular weight cutoff (Millipore).
Purified CPI-17 was diluted into PKC buffer (25 mM MOPS, pH 7.2; 12.5 mM b-glycerophosphate,
25 mM MgCl2,5 mM NaF, 0.25 mM DTT, 0.025% Tween20, 5 mM b-mercaptoethanol, and 5% glyc-
erol) supplemented with PKC lipid activator (Millipore, catalog #20–133). CPI-17 was then phosphor-
ylated in vitro by PKCd (SignalChem, catalog #P64-10G) in the presence of 10–100 mM ATP and
g-32P-ATP (50 mCi at 6000 Ci/mmol). Reactions were incubated at 30˚C overnight. Proteins were
purified away from reaction components and desalted using Micro Bio-Spin six columns (Bio-Rad)
equilibrated with B3 buffer (25 mM Tris, pH 7.5; 150 mM NaCl; 0.01 mg/ml bovine serum albumin;
0.05% Tween20; 5 mM b-mercaptoethanol, 5% glycerol). For some studies, the CPI-17 protein was
thiophosphorylated by PKCd in the presence of 1 mM [g-35S]thio-ATP. Control experiments showed
that purified MLCP did not detectably dephosphorylate [g-35S]thio(p)CPI-17.
Human myosin regulatory light chain (MRLC, also called MYL9) cDNA was obtained from GE-
Dharmacon (clone accession number BC002648) and used to create an N-terminal maltose binding
protein fusion in the vector pMAL-C2X (New England Biolabs). MBP-tagged MRLC was expressed in
E. coli as previously described (Castilho et al., 2009; Williams et al., 2014). For 32P-labeling by
myosin light-chain kinase [MLCK (1425–1776); Sigma-Aldrich catalog #M9197) purified MRLC was
diluted into MLCK buffer (20 mM MOPS, pH 7.2; 12.5 mM b-glycerophosphate, 25 mM MgCl2,5 mM
EDTA, 2 mM EGTA, 5 mM NaF, 0.25 mM DTT, and 5% glycerol) in the presence of 5 mM CaCl2,
0.0375 mg/ml calmodulin, 100 mM ATP and [g-32P]ATP (50 mCi of 6000 Ci/mmol). Reactions were incu-
bated at 30˚C overnight. MRLC was purified away from the kinase and other reaction components,
eluted with glutathione, and desalted and concentrated using Amicon Ultra-4 10K centrifugal filters
(Millipore) and buffer B3.
Ezrin GST-C-ERMAD recombinant protein produced in E. coli and LOK kinase produced in
HEK293 CRL-1573 cells were purified according to Viswanatha et al. (2014). GST-C-ERMAD bound
to glutathione agarose beads was labelled with LOK kinase in the presence of [g-32P]ATP, and eluted
with glutathione according to protocols of Viswanatha et al. (2014).
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Bovine myelin basic protein (MyBP) was from Millipore and was 32P-phosphorylated in vitro by
Protein Kinase A (New England Biolabs) using methods previously described (Castilho et al., 2009;
Williams et al., 2014).
Phosphatase assays with purified components
Purified holoenzymes were diluted to the appropriate concentrations in reaction buffer (20 mM Tris,
pH 7.5; 150 mM NaCl), while substrates and inhibitors were diluted in buffer B3; see figure legends
for specific concentrations and conditions. In general, 6 ml phosphatase assays were made up of 2 ml
enzymes, 2 ml of substrate, and 2 ml of buffer/inhibitors. Reactions containing no enzyme were
included as controls to demonstrate that the substrates did not contain phosphatase activity. A time
course pilot experiment was performed for each extract/substrate combination to ensure that the
assays were performed in the linear range (Figure 2—figure supplement 1, Figure 6 and Figure 7—
figure supplement 2). All experiments investigating rates of pCPI-17 dephosphorylation were per-
formed with the Ala12 mutation described above to ensure more precise quantitation. For okadaic
acid (OA) and calyculin A inhibition experiments (Figure 4), the inhibitors were serially diluted in
DMSO, and then mixed with MLCP and incubated 10 min on ice before the addition of substrates.
Phosphatase assays were stopped with trichloracetic acid (TCA) after a time at which <20% (typically
in the range of 5–10%) of the substrate was dephosphorylated. The supernatant was mixed with
ammonium molybdate and extracted with heptane-isobutyl alcohol according to Mochida and
Hunt, 2007. 32P release was then measured using a PerkinElmer liquid scintillation counter (Tri-Carb
2810TR). Data were analyzed and statistics were generated by non-linear regression to Michaelis-
Menten kinetics using Prism 6 software (GraphPad Software).
For the experiments detailed in Figure 9—figure supplement 1, MLCP was first thiophosphory-
lated by ROCK-II (Millipore, catalog #11–552) as follows. MLCP (0.5 nM) and ROCK-II (2.5 nM) were
incubated at 30˚C for 90 min in the presence of 0.1 mM g-thio-ATP, as described in Khasnis et al.
(2014). After thiophosphorylation, standard phosphatase assays were performed as detailed in the
figure legend.
Phosphatase assays in cell extracts
Mouse uteri were dissected in phosphate-buffered saline (PBS) and immediately frozen in liquid
nitrogen until use. Uteri were homogenized in ice-cold TPER buffer (ThermoFisher Scientific) supple-
mented with 1 Halt protease inhibitor (ThermoFisher Scientific), 1x Protease inhibitor tablet
(Pierce), 0.1 mg/ml Soybean Trypsin Inhibitor (Sigma), and 1 mM phenylmethylsulfonylfluoride
(PMSF; Sigma). This combination of protease inhibitors was essential for prevention of enzyme and
substrate degradation in the extract. After centrifugation, the extract supernatant was assayed for
phosphatase activity against the substrates described above. A typical assay would be composed of
3 ml of extract mixed with 1 ml of substrate. For OA titration, the drug was serially diluted in DMSO
and mixed 1/10 in the extract, which was then incubated 10 min on ice before addition of substrate.
For kinetic studies, [32P]pCPI-17 was added at concentrations detailed in the figure legends. Phos-
phatase assays were performed as described previously (Castilho et al., 2009; Williams et al.,
2014).
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